-
Innovative CRISPR strategy resensitizes lung cancer to treatment
17 Nov 2025 18:25 GMT
… reverse chemotherapy resistance in lung cancer. The approach restores drug … Editing Institute
Potential beyond lung cancer
The study focused on … Cas9, the team engineered lung cancer cells with the R34G … such as carboplatin and paclitaxel. In animal models, …
-
CRISPR unlocks a new way to defeat resistant lung cancer
17 Nov 2025 15:53 GMT
… CRISPR technology can make lung cancer cells responsive to chemotherapy … lung cancer (NSCLC) that represents 20% to 30% of all lung cancer … #47;Cas9 to engineer lung cancer cells carrying the R34G … drugs such as carboplatin and paclitaxel. In animal models, …
-
The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study
14 Nov 2025 21:29 GMT
… A. Evolving trends in lung cancer: epidemiology, diagnosis, and … combination of albumin-bound paclitaxel, anlotinib and PD-1 … advanced non-small cell lung cancer. Lung Cancer. 2018;122:32–37 … in non-small cell lung cancer (NSCLC). Lung Cancer. 2024;187:107438 …
-
The Intricate Web of MicroRNAs in Modulating EGFR-TKI Resistance in Non-Small Cell Lung Cancer: A Comprehensive Review
11 Nov 2025 07:13 GMT
… osimertinib resistance in lung cancer by inhibiting the … . Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N … sensitizing EGFR mutations in lung cancer activate anti-apoptotic … non-small cell lung cancer. Transl Lung Cancer Res. 2022;11 …
-
Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents’ Delivery Against Lung Cancer: A Review
24 Oct 2025 14:10 GMT
… lung cancer into non-small cell lung cancer (NSCLC) and small cell lung cancer … of lung cancer.
Current treatment modalities for lung cancer include … chemotherapeutic agents like cisplatin, paclitaxel, and docetaxel (DTX … CPT-NPs inhibited lung tumor growth by …
-
[ESMO 2025] Bivalent antibody ivonescimab shows potential as a 1st-line treatment for lung cancer
20 Oct 2025 05:30 GMT
… achieved significant results in a lung cancer study comparing it to Tevimbra … metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 … groups received four cycles of paclitaxel (175 mg/m²) and …
-
Pulsed Low-Dose-Rate Chemoradiation Therapy Reduces Side Effects Without Compromising Efficacy in Esophageal and Non-Small Cell Lung Cancer Patients
30 Sep 2025 21:39 GMT
… and non-small cell lung cancers. This approach, termed … protocols employing carboplatin and paclitaxel. The regimen spanned … for esophageal and select lung cancer patient populations.
Further … induced esophagitisnon-small cell lung cancer therapypulsed low-dose- …
-
Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs
16 Nov 2025 19:56 GMT
… called “PIKTOR,” alongside the chemotherapy paclitaxel as a treatment for endometrial … or refractory non-small cell lung cancer. With the new capital, the …
-
<![CDATA[Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial]]>
11 Sep 2025 17:43 GMT
… cell lung cancer is the most aggressive type of lung cancer with … in combination with either paclitaxel or topotecan for … than non-small cell lung cancer. Lung cancer is the second most … Patients With Small-cell Lung Cancer in Combination With Chemotherapy …
-
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
08 Sep 2025 15:00 GMT
… Lung Cancer in Barcelona. “Small cell lung cancer is the most aggressive type of lung cancer … -stage small cell lung cancer (Cohort 1) … of pumitamig plus paclitaxel, or topotecan in … Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancer …
About
© 1995-2025